CAS 521-18-6|Stanolone
Introduction：Basic information about CAS 521-18-6|Stanolone, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | Stanolone | ||
|---|---|---|---|
| CAS Number | 521-18-6 | Molecular Weight | 290.440 |
| Density | 1.1±0.1 g/cm3 | Boiling Point | 413.1±38.0 °C at 760 mmHg |
| Molecular Formula | C19H30O2 | Melting Point | 178-183 °C |
| MSDS | ChineseUSA | Flash Point | 176.4±19.4 °C |
| Symbol | GHS02, GHS06, GHS08 | Signal Word | Danger |
Names
| Name | 17β-hydroxy-5α-androstan-3-one |
|---|---|
| Synonym | More Synonyms |
Chemical & Physical Properties
| Density | 1.1±0.1 g/cm3 |
|---|---|
| Boiling Point | 413.1±38.0 °C at 760 mmHg |
| Melting Point | 178-183 °C |
| Molecular Formula | C19H30O2 |
| Molecular Weight | 290.440 |
| Flash Point | 176.4±19.4 °C |
| Exact Mass | 290.224579 |
| PSA | 37.30000 |
| LogP | 3.75 |
| Vapour Pressure | 0.0±2.2 mmHg at 25°C |
| Index of Refraction | 1.536 |
| InChIKey | NVKAWKQGWWIWPM-ABEVXSGRSA-N |
| SMILES | CC12CCC3C(CCC4CC(=O)CCC43C)C1CCC2O |
Toxicological Information
CHEMICAL IDENTIFICATION |
ACUTE TOXICITY DATA - TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Subcutaneous
- DOSE :
- 17500 ug/kg
- SEX/DURATION :
- female 35 day(s) pre-mating
- TOXIC EFFECTS :
- Reproductive - Fertility - female fertility index (e.g. # females pregnant per # sperm positive females; # females pregnant per # females mated)
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Subcutaneous
- DOSE :
- 160 mg/kg
- SEX/DURATION :
- female 14-21 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Specific Developmental Abnormalities - urogenital system
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Subcutaneous
- DOSE :
- 1400 ug/kg
- SEX/DURATION :
- female 14 day(s) pre-mating
- TOXIC EFFECTS :
- Reproductive - Maternal Effects - uterus, cervix, vagina Reproductive - Fertility - other measures of fertility
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Subcutaneous
- DOSE :
- 700 ug/kg
- SEX/DURATION :
- female 14 day(s) pre-mating
- TOXIC EFFECTS :
- Reproductive - Maternal Effects - ovaries, fallopian tubes
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Intramuscular
- DOSE :
- 80 mg/kg
- SEX/DURATION :
- female 13-20 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Specific Developmental Abnormalities - skin and skin appendages Reproductive - Specific Developmental Abnormalities - urogenital system
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Parenteral
- DOSE :
- 2500 ug/kg
- SEX/DURATION :
- female 10 day(s) pre-mating
- TOXIC EFFECTS :
- Reproductive - Maternal Effects - ovaries, fallopian tubes
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Parenteral
- DOSE :
- 168 mg/kg
- SEX/DURATION :
- male 1 day(s) pre-mating
- TOXIC EFFECTS :
- Reproductive - Paternal Effects - prostate, seminal vesicle, Cowper's gland, accessory glands
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Implant
- DOSE :
- 24 mg/kg
- SEX/DURATION :
- male 42 day(s) pre-mating
- TOXIC EFFECTS :
- Reproductive - Paternal Effects - testes, epididymis, sperm duct Reproductive - Fertility - male fertility index (e.g. # males impregnating females per # males exposed to fertile nonpregnant females) Reproductive - Fertility - litter size (e.g. # fetuses per litter; measured before birth)
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Unreported
- DOSE :
- 150 mg/kg
- SEX/DURATION :
- female 30 day(s) pre-mating
- TOXIC EFFECTS :
- Reproductive - Maternal Effects - uterus, cervix, vagina
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Subcutaneous
- DOSE :
- 40 mg/kg
- SEX/DURATION :
- female 1 day(s) pre-mating
- TOXIC EFFECTS :
- Reproductive - Maternal Effects - ovaries, fallopian tubes Reproductive - Fertility - litter size (e.g. # fetuses per litter; measured before birth) Reproductive - Fertility - other measures of fertility
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Subcutaneous
- DOSE :
- 40 mg/kg
- SEX/DURATION :
- female 10 day(s) pre-mating
- TOXIC EFFECTS :
- Reproductive - Maternal Effects - uterus, cervix, vagina Reproductive - Maternal Effects - other effects
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Subcutaneous
- DOSE :
- 2 gm/kg
- SEX/DURATION :
- female 14 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Specific Developmental Abnormalities - skin and skin appendages
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Subcutaneous
- DOSE :
- 24 mg/kg
- SEX/DURATION :
- female 3 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Maternal Effects - uterus, cervix, vagina
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Intramuscular
- DOSE :
- 200 ug/kg
- SEX/DURATION :
- male 20 day(s) pre-mating
- TOXIC EFFECTS :
- Reproductive - Paternal Effects - spermatogenesis (incl. genetic material, sperm morphology, motility, and count)
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Intramuscular
- DOSE :
- 14 mg/kg
- SEX/DURATION :
- male 70 day(s) pre-mating
- TOXIC EFFECTS :
- Reproductive - Paternal Effects - spermatogenesis (incl. genetic material, sperm morphology, motility, and count)
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Implant
- DOSE :
- 3420 ug/kg
- SEX/DURATION :
- male 90 day(s) pre-mating
- TOXIC EFFECTS :
- Reproductive - Paternal Effects - testes, epididymis, sperm duct
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Subcutaneous
- DOSE :
- 30 mg/kg
- SEX/DURATION :
- female 1-3 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Fertility - pre-implantation mortality (e.g. reduction in number of implants per female; total number of implants per corpora lutea)
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Unreported
- DOSE :
- 1500 ug/kg
- SEX/DURATION :
- female 1-3 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Fertility - pre-implantation mortality (e.g. reduction in number of implants per female; total number of implants per corpora lutea)
MUTATION DATA - TEST SYSTEM :
- Non-mammalian species
- DOSE/DURATION :
- 12 mg/8W (Intermittent)
- REFERENCE :
- JEZOAO Journal of Experimental Zoology. (Alan R. Liss, Inc., 41 E. 11th St., New York, NY 10003) V.1- 1904- Volume(issue)/page/year: 205,403,1978
- TEST SYSTEM :
- Non-mammalian species
- DOSE/DURATION :
- 12 mg/8W (Intermittent)
- REFERENCE :
- JEZOAO Journal of Experimental Zoology. (Alan R. Liss, Inc., 41 E. 11th St., New York, NY 10003) V.1- 1904- Volume(issue)/page/year: 205,403,1978
Safety Information
| Symbol | GHS02, GHS06, GHS08 |
|---|---|
| Signal Word | Danger |
| Hazard Statements | H225-H301 + H311 + H331-H370 |
| Precautionary Statements | P210-P280-P302 + P352 + P312-P304 + P340 + P312-P370 + P378-P403 + P235 |
| Personal Protective Equipment | Eyeshields;full-face particle respirator type N100 (US);Gloves;respirator cartridge type N100 (US);type P1 (EN143) respirator filter;type P3 (EN 143) respirator cartridges |
| Hazard Codes | Xn |
| Risk Phrases | R61 |
| Safety Phrases | S53-S36/37/39-S45 |
| RIDADR | UN1230 - class 3 - PG 2 - Methanol, solution |
| WGK Germany | 3 |
| RTECS | BV8052000 |
| Packaging Group | II |
| Hazard Class | 6.1 |
Articles2532
More Articles| Genetic and pharmacologic inhibition of eIF4E reduces breast cancer cell migration, invasion, and metastasis. Cancer Res. 75(6) , 1102-12, (2015) The translation initiation factor eIF4E is an oncogene that is commonly overexpressed in primary breast cancers and metastases. In this article, we report that a pharmacologic inhibitor of eIF4E funct... | |
| Aptamer-based polyvalent ligands for regulated cell attachment on the hydrogel surface. Biomacromolecules 16(4) , 1382-9, (2015) Natural biomolecules are often used to functionalize materials to achieve desired cell-material interactions. However, their applications can be limited owing to denaturation during the material funct... | |
| Co-ordinated brain and craniofacial development depend upon Patched1/XIAP regulation of cell survival. Hum. Mol. Genet. 24(3) , 698-713, (2015) Congenital brain and craniofacial defects often occur together as a consequence of their developmental dependency on common progenitor tissue interactions and signaling pathways during embryogenesis. ... |
Synonyms
| Stanolone |
| EINECS 208-307-3 |
| Anaboleen |
| 17β-Hydroxy-5α-androstane-3-one |
| Androlone |
| dihydrotestosterone |
| Anabolex |
| (5a,17b)-17-Hydroxyandrostan-3-one |
| 5α-Dihydrotestosterone |
| Stanorone |
| 5α dihydrotestosterone |
| Androstanolone |
| DHT |
| [14C]-Dihydrotestosterone |
| Androstan-3-one, 17-hydroxy-, (5α,17β)- |
| 5α-Androstan-3-one, 17β-hydroxy- |
| [3H]-Dihydrotestosterone |
| 17beta-hydroxy-5alpha-androstan-3-one |
| Andractim |
| 17β-hydroxy-5α-androstan-3-one |
| Androstan-17b-ol-3-one |
| Stanaprol |
| 4-dihydrotestosterone |
| Neodrol |
| (5α,17β)-17-Hydroxyandrostan-3-one |
| 5a-Dihydrotestosterone |
| Protona |
| Stanolon |
| Anaprotin |
| MFCD00003667 |
